Tesamore DS [Tesamorelin 100mg] – 10 Vials – Corey Pauling

Laboratory: Corey Pauling
Form: Subcutaneous injection
Molecule: Tesamorelin
Concentration: 10mg/vial
Volume: 10 vials
Tesamore DS [10mg X 10 vials] contains Tesamorelin, a synthetic analogue of growth hormone-releasing factor (GHRF) that stimulates endogenous growth hormone and IGF-1 production. It is clinically studied for its effects on body composition, particularly visceral fat reduction, and has also been associated with improvements in lean tissue and muscle quality in selected populations.

Description and Effects

TESAMORE DS [Tesamorelin 10mg X 10 vials] contains tesamorelin, a synthetic analogue of growth hormone-releasing factor (GHRF/GHRH) that stimulates the body's natural production and release of growth hormone. Tesamorelin increases growth hormone and IGF-1 activity and has been clinically studied for its effects on body composition, particularly visceral abdominal fat. For athletes and physically active individuals, tesamorelin is of particular interest for its potential role in body composition management, visceral fat reduction, and the maintenance of lean tissue.

Product Benefits

• Visceral Fat Reduction: Supports a reduction in visceral adipose tissue, the metabolically active fat stored around the abdominal organs.
• Body Composition Support: Clinical studies have reported favorable changes in body composition, including reductions in visceral fat and improvements in lean body mass in selected populations.
• Growth Hormone Stimulation: Stimulates endogenous growth hormone release, resulting in increased circulating IGF-1 levels.
• Muscle Quality Support: Research has reported improvements in muscle area and muscle density in certain tesamorelin-treated populations with significant reductions in visceral adipose tissue.

Usage Guidelines

• Clinical Dosage: The approved 2mg/vial formulation of tesamorelin is administered at 1.4mg subcutaneously once daily. Dosage recommendations vary between formulations and should not be transferred between different tesamorelin products.
• Administration: Tesamorelin is administered by subcutaneous injection, typically into the abdominal area. Injection sites should be rotated.
• Protocol: Clinical use involves regular daily administration. Athletic protocols should not be extrapolated directly from the approved medical dosing without considering the specific formulation and concentration.

Precautions and Wellness

• Possible Side Effects: Common adverse effects may include injection-site reactions, joint or muscle pain, peripheral edema, numbness or tingling, and headache.
• Glucose Control: Tesamorelin can impair glucose tolerance and may increase the risk of developing diabetes. Blood glucose should be evaluated and monitored during use.
• IGF-1 Monitoring: Tesamorelin increases circulating IGF-1. Persistent elevations should be monitored, particularly during prolonged use.
• Contraindications: Tesamorelin is contraindicated in pregnancy, active malignancy, known hypersensitivity to tesamorelin, and conditions involving disruption of the hypothalamic-pituitary axis.
• Storage: Store and reconstitute according to the specific product instructions. Storage requirements can vary between tesamorelin formulations.